Takeda Reacquires Rights to Diabetes Drug in Canada
"Reacquiring the commercial rights to ACTOS is Takeda's first opportunity to establish a commercial presence in Canada," said Daaron Dohler, general manager at Takeda Canada. "It also underscores Takeda's ongoing efforts to reinforce our global operations and build a stronger presence in North America."
ACTOS was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000. Takeda has taken over responsibility for ACTOS in the Canadian market effective mid-June. The company already sells ACTOS in many other territories, including the United States, Japan and most of Europe.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.